Health Care
AIDA STEMI TRIAL presentation slides
Welcome to this Science-to-Strategy Summit
National Experts in Cardiovascular Medicine Illuminate and Debate Illuminate and Debate New Frontiers in Atrial Fibrillation Emerging Perspectives in.
The Evolving Science and Controversial Landscape of Antiplatelet Therapy in the Catheterization Laboratory Mechanisms Mortality Therapeutics PROGRAM CO-CHAIRMAN.
Preliminary Results A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy Immediate Versus Delayed Invasive Strategy in Patients.
CHARISMA Genomics Deepak L. Bhatt MD, MPH, Katy L. Simonsen PhD, Eileen S. Emison PhD, Keith A. A. Fox MBChB, P. Gabriel Steg MD, Gilles Montalescot MD,
Two-Year Follow-up from a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal.
Voluntary disclosures in the Annual Report signal success Stephen Wong Siu Kei (50184032) Tony Chan Sai Chung (50183940)
Edward P. Sloan, MD, MPH EMRA/FERNE ED Documentation Session: Optimizing the Care of ED Patients with Neurological Emergencies.
Mind the Gap: AF and Evolving Strategies in Anticoagulation Fred M. Kusumoto, MD, FACC Mayo Clinic Tracy Y. Wang, MD, MHS, FACC Duke Clinical Research.
Dedication-Clemmensen
